Ranbaxy recalls generic Lipitor in United States

MUMBAI Fri Nov 23, 2012 11:50pm IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) has recalled its generic version of Pfizer Inc's (PFE.N) cholesterol-lowering drug Lipitor in the United States after certain batches were found to contain glass particles.

Ranbaxy's U.S. subsidiary, Ranbaxy Pharmaceuticals Inc, said the recall affects certain lots of 10-, 20- and 40-milligram doses of the drug, known generically as atorvastatin calcium. The 80-milligram dosage is not affected.

The company is conducting an investigation which it expects will take two weeks. It did not report any injuries connected to the tainted pills and did not say how the problem was discovered.

The recall could cause shortages of the drug in the United States, analysts said. Ranbaxy, the first company to introduce generic Lipitor after Pfizer's patent expired in November 2011, controls about 60 percent of the market, according Ross Muken, an analyst at ISI Group LLC.

"Given its dominant share of this high-volume drug, we are certain to see supply shortages over the next two weeks," Muken said. The near-term impact is likely to be felt most by retail pharmacies and more modestly by wholesalers, he added.

The recall is the latest in a series of manufacturing problems at Ranbaxy, which is operating under heightened scrutiny following a long-running dispute with the U.S. Food and Drug Administration.

In 2008 the FDA banned the company from importing about 30 drugs after it found manufacturing deficiencies at two of the company's facilities in India. In 2009 the U.S. government accused Ranbaxy of falsifying data used in drug applications.

Last December, Ranbaxy agreed to make changes to its manufacturing plants in the United States and India. And it said it would set aside $500 million to resolve any potential civil or criminal charges stemming from an investigation by the U.S. Department of Justice.

Under a proposed settlement earlier this year, Ranbaxy agreed to engage a third party to conduct a review of its facilities, implement procedures to ensure data integrity in its marketing applications, and ensure it meets good manufacturing practices.

During its first six months on the market, when it enjoyed marketing exclusivity, atorvastatin generated sales of nearly $600 million for Ranbaxy, according to Bhagwan Singh Chaudhary, a research associate at the brokerage IndiaNivesh.

"The (recall) will impact the company's credibility," said Chaudhary. "A recall suggests corrective measures suggested by the U.S. FDA are not being implemented."

Other drugmakers, including Indian rival Dr. Reddy's Laboratories Ltd (REDY.NS), have launched their own versions of Lipitor, and the market has become more competitive.

In 2008, Japan's Daiichi Sankyo Co (4568.T) acquired a majority stake in Ranbaxy in a deal valued at $4.2 billion.

Shares of Ranbaxy, which is valued at $3.93 billion, fell 3.3 pct to 496 rupees in Mumbai .BSESN. (Additional reporting by Toni Clarke in Boston. Editing by Chris Gallagher, Matt Driskill and John Wallace)

FILED UNDER:
  • Most Popular
  • Most Shared

Insight

REUTERS SHOWCASE

Border Talks

Border Talks

India names Ajit Doval as special envoy for China border talks.  Full Article 

WTO Deal

WTO Deal

U.S. seeks to step up India trade talks  Full Article 

Phone Masts

Phone Masts

American Tower to buy Bharti Nigeria phone masts for $1.1 billion  Full Article 

Infrastructure Plan

Infrastructure Plan

India targets private cash to build railways to its ports.  Full Article 

Shadow Banking

Shadow Banking

Reserve Bank planning more measures for NBFCs.  Full Article 

Auto Sector

Auto Sector

Hyundai Motor, Kia Motors lift 2014 global sales target on China, emerging markets  Full Article 

Oil Prices

Oil Prices

Some fund managers see oil falling to $60 without OPEC cut.  Full Article 

Project Shelved

Project Shelved

Jindal Steel shelves $10 bln project after coal setback.  Full Article 

Market Eye

Market Eye

Sensex, Nifty rise to record after China, ECB stimulus boosts risk appetite.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage